Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.42 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.34 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356031 | 0.93 | HRH3 (0.39) | SYKHRH3ACACBFGFR1SLC9A3 | |
| SCHEMBL353143 | 0.92 | HDAC8 (0.39) | SYKGCKHRH3ACACBFGFR1 | |
| SCHEMBL353867 | 0.83 | HDAC8 (0.39) | SYK | |
| SCHEMBL353421 | 0.82 | FGFR1 (0.40) | SYKFGFR1SLC9A3 | |
| SCHEMBL355960 | 0.81 | FGFR1 (0.39) | SYKFGFR1 | |
| SCHEMBL15981203 | 0.81 | SYK (0.38) | SYKSLC9A3 | |
| SCHEMBL10247293 | 0.81 | SYK (0.38) | SYKSLC9A3KMT2AGSK3B | |
| SCHEMBL10247112 | 0.80 | HDAC8 (0.42) | SYK | |
| SCHEMBL354136 | 0.80 | PKM (0.37) | SYKHRH3 | |
| SCHEMBL10254656 | 0.80 | CHEK2 (0.41) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2012012322-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | SYK 1676/4885GCK 3235/4885HRH3 56/4885 |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | SYK 2535/4885GCK 2364/4885HRH3 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.